Breaking News

AMRI Completes Cedarburg Acquisition

April 7, 2014

Expands resources for complex drug development services and products

AMRI has completed the acquisition of Cedarburg Pharmaceuticals, Inc. for a total consideration of $41 million, including assumption of certain liabilities.
The acquisition of Cedarburg, a contract developer and manufacturer of technically complex API's for both generic and branded drug products, is part of AMRI's strategy to expand its presence as a supplier of custom and complex drug development services and product. Customers will now have access to expanded resources, including development of complex API, expanded scale-up capabilities and large-scale manufacturing.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important